139 related articles for article (PubMed ID: 35017453)
1. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
Jacobs TG; van Aerde KJ; Colbers A; Burger DM
Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
[TBL] [Abstract][Full Text] [Related]
3. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
6. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
[TBL] [Abstract][Full Text] [Related]
7. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
11. Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
Ciccullo A; Baldin G; Borghi V; Lassandro AP; Farinacci D; Guaraldi G; Mussini C; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2021 May; 37(5):333-334. PubMed ID: 33587009
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
Kreutzwiser D; Sheehan N; Dayneka N; Lemire B; Wong A; Samson L; Brophy J
Antivir Ther; 2017; 22(6):545-549. PubMed ID: 28198351
[TBL] [Abstract][Full Text] [Related]
14.
Mathew JM; Mpangase PT; Sengupta D; Kwenda S; Mavri-Damelin D; Ramsay M
Pharmacogenomics; 2021 Oct; 22(15):963-972. PubMed ID: 34528449
[No Abstract] [Full Text] [Related]
15. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
16. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.
Mpofu R; Kawuma AN; Wasmann RE; Akpomiemie G; Chandiwana N; Sokhela SM; Moorhouse M; Venter WDF; Denti P; Wiesner L; Post FA; Haas DW; Maartens G; Sinxadi P
Br J Clin Pharmacol; 2024 May; 90(5):1247-1257. PubMed ID: 38332460
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
18. Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir.
Calza L; Borderi M; Colangeli V; Testi D; Amedeo A; Bon I; Re MC; Viale P
AIDS Res Hum Retroviruses; 2021 Mar; 37(3):204-206. PubMed ID: 33126811
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
[TBL] [Abstract][Full Text] [Related]
20. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
